In 1984, during my intern year, I admitted the first of what would become thousands of young men dying from a disease we were only beginning to understand. Our wards and ICUs overflowed with patients suffering from infections that should not have been possible – many we could not even name, let alone treat. We careened forward while looking only in the rearview mirror, each death teaching us what we should have known the week before.
The federal response was criminally slow. anthony Fauci wouldn’t get serious NIH funding for HIV research until 1986 – five years and thousands of deaths later. But medicine didn’t wait for Washington. The Gay Men’s Health Crisis (GMHC) was founded in January 1982 when six gay men met in Larry kramer’s apartment. An answering machine in volunteer Rodger McFarlane’s home became the world’s first AIDS hotline. By 1984, the CDC asked GMHC to assist them in creating public conferences on AIDS. GMHC’s budget grew from $165,000 in 1982 to $783,000 in 1983 and $1.4 million by 1985 – entirely from private donations.And while the government continued to abandon us, activists created the landmark buddy Program to assist people with AIDS with day-to-day needs – the model for patient support that didn’t exist anywhere else.
That story matters now.That roughly $3 billion NIH cut isn’t getting reversed.Not this year, probably not next. We can spend extended time writing op-eds demanding restoration, or we can do what we did in the ’80s. Adapt. Survive. Keep the research infrastructure alive until the politics shift.
I’ve lived this crisis before. Here’s what actually works when federal funding collapses.
1. Build a formal underground research network
Table of Contents
During the AIDS epidemic, researchers shared tissue samples, unpublished data, and experimental protocols through informal channels, bypassing the usual grant-dependent publication cycle. Someone at the University of California San Francisco would FedEx samples to a lab at New York University. Negative results got passed around via fax. we couldn’t wait for peer review when people were dying.
The same holds true today,and it should be formalized. Major academic medical centers should create a consortium – call it the Orphan Research Collaborative – with shared biobanks, open data repositories, and fast-track peer review specifically for research the pharmaceutical industry won’t touch. Antibiotic resistance. Rare diseases affecting small populations. Tropical diseases with no U.S. market.Not as a supplement to NIH funding, but as a parallel system that operates regardless of federal budgets.
The technology exists. The expertise exists. What’s missing is the institutional will to formalize what desperate researchers always do anyway when the money dries up.
2. Restructure how we credit academic work
The current promotion system rewards researchers who land big federal grants. When those grants d
The Urgent Need for a Hybrid Funding Model in Biomedical Research
The current landscape of biomedical research funding demands a proactive, adaptable approach. While robust and sustained federal investment remains the ideal, waiting for political consensus can hinder progress and jeopardize lives.A hybrid funding model – one that mirrors the rapid iteration and collaborative spirit observed among scientists sharing failures and successes – is not merely a stopgap, but a strategic imperative. This approach, built on unconventional partnerships and resilient systems, will ensure American biomedical research not only survives the current funding crisis but emerges stronger and more innovative.
The Lessons of the AIDS Epidemic
Dr. robert B. Shpiner, a clinical professor of medicine at UCLA with over 40 years of ICU experience, draws a powerful parallel to the early days of the AIDS epidemic. In the 1980s, facing a rapidly escalating crisis and initial political inaction, the AIDS research community didn’t passively await federal support. Rather, they proactively constructed “parallel funding streams, unconventional partnerships, and new institutional models.” https://www.statnews.com/2024/02/29/biomedical-research-funding-hybrid-model-aids-epidemic/
This wasn’t a surrender to budgetary constraints, but a strategic maneuver. Many initiatives failed, but the successes created a crucial infrastructure that was ready to effectively utilize federal funding when it finally became available in the 1990s. This demonstrates the power of building systems that function regardless of the political climate.
Why a Hybrid Model is Crucial Now
Today, biomedical research faces a similar challenge. Funding from the National Institutes of Health (NIH), the primary federal source for biomedical research, has faced stagnation and increasing competition. https://www.nih.gov/ This creates uncertainty and slows down critical research.
A hybrid model addresses this by:
* Diversifying Funding Sources: Reducing reliance on a single funding source (the federal government) makes research less vulnerable to political shifts and budget cuts. This can include philanthropic organizations, private industry partnerships, and venture capital.
* Accelerating Innovation: The collaborative, iterative approach championed by scientists – openly sharing failures and building on each other’s work – is often stifled by conventional, siloed funding structures.A hybrid model can foster this environment.
* Building resilience: Creating self-reliant systems ensures that research can continue even during periods of funding scarcity.
* Rapid Response Capabilities: As Dr. Shpiner points out, waiting for perfect solutions can be fatal. A hybrid model allows for a “field medicine approach” – stabilizing critical research areas and positioning them for recovery.
Components of a Successful Hybrid Model
While the specifics will vary, a successful hybrid model should include:
* Philanthropic Partnerships: Increased collaboration with foundations and individual donors focused on specific disease areas or research priorities.Organizations like the Bill & Melinda gates foundation and the American Cancer Society already play a important role, but expanded partnerships are needed. https://www.gatesfoundation.org/ https://www.cancer.org/
* Industry Collaboration: Strategic partnerships with pharmaceutical and biotechnology companies, offering funding and resources in exchange for access to research findings and potential commercialization opportunities. careful consideration must be given to maintaining scientific integrity and openness in these collaborations.
* Venture Philanthropy: Investing in early-stage research with the potential for high impact, similar to venture capital but with a focus on social return rather than purely financial profit.
* Streamlined Grant Processes: Reducing bureaucratic hurdles and simplifying the submission process for non-federal funding sources.
* Data Sharing Platforms: Creating secure and accessible platforms for researchers to share data and findings,accelerating discovery and reducing redundancy.
Key Takeaways
* Federal funding is vital, but not sufficient: A diversified funding approach is essential for long-term stability.
* The AIDS epidemic offers a blueprint: Proactive, community-driven funding models can be highly effective.
* Collaboration is key: Breaking down silos and fostering open communication accelerates innovation.
* Resilience is paramount: Building systems that can withstand political and economic fluctuations is crucial.
Looking Ahead
The current funding crisis in biomedical research is a challenge, but also an prospect. By embracing a hybrid funding model,we can build a more resilient,innovative,and impactful research ecosystem. The choice is clear: we can lament the current situation, or we can proactively build the systems that will ensure American biomedical research continues to lead the world in improving human health.
Keep reading